FaithENathanMD
Oncology • Moorestown, NJGenitourinary Oncology, Hematologic Oncology, Thoracic Cancer
Retired
Dr. Nathan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9 W Walnut Ave
Moorestown, NJ 08057Phone+1 856-802-1183
Summary
- Dr. Faith Nathan is an oncologist in Moorestown, NJ. She received her medical degree from Rutgers New Jersey Medical School and has been in practice 30 years. She specializes in genitourinary oncology, hematologic oncology, and thoracic cancer and is experienced in immunotherapy, urologic oncology, thoracic oncology, clinical trials as topic, and lung neoplasms. She has more than 40 publications and over 500 citings. She retired in July 2023.
Education & Training
Drexel University College of Medicine/Hahnemann University HospitalFellowship, Hematology and Medical Oncology, 1989 - 1992
Cooper Medical School of Rowan University/Cooper University HospitalResidency, Internal Medicine, 1987 - 1989
Rutgers New Jersey Medical SchoolClass of 1986
Certifications & Licensure
NJ State Medical License 1987 - 2023
PA State Medical License 1988 - 2006- American Board of Internal Medicine Internal Medicine
Clinical Trials
- A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel Start of enrollment: 2006 Mar 01
Publications & Presentations
PubMed
- 385 citationsNivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung CancerScott N. Gettinger, Naiyer A. Rizvi, Laura Qm Chow, Hossein Borghaei, Julie R. Brahmer
Journal of Clinical Oncology. 2016-09-27 - 1637 citationsNivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.Matthew D. Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, B. Zurawski, Sang-We Kim
The New England Journal of Medicine. 2019-09-28 - 2137 citationsNivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D. Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Gregory A. Otterson
The New England Journal of Medicine. 2018-04-16
Journal Articles
- Pain in castration-resistant prostate cancer with bone metastases: a qualitative studyGater A, Abetz-Webb L, Battersby C, Parasuraman B, McIntosh S, Nathan F, Piault EC, Health & Quality of Life Outcomes, 2011
- Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care populationEngel-Nitz NM, Alemayehu B, Parry D, Nathan F, Cancer management and research, 2011
- A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advan...Chouaid C, Nathan F, Pemberton K, Morris T, Cancer Chemother Pharmacol, 2011
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
